CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia. CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease